CytomX Therapeutics (CTMX) Accumulated Depreciation & Amortization (2016 - 2024)
Historic Accumulated Depreciation & Amortization for CytomX Therapeutics (CTMX) over the last 11 years, with Q4 2024 value amounting to $16.2 million.
- CytomX Therapeutics' Accumulated Depreciation & Amortization rose 1050.52% to $16.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was $16.2 million, marking a year-over-year increase of 1050.52%. This contributed to the annual value of $16.2 million for FY2024, which is 1050.52% up from last year.
- According to the latest figures from Q4 2024, CytomX Therapeutics' Accumulated Depreciation & Amortization is $16.2 million, which was up 1050.52% from $14.7 million recorded in Q4 2023.
- In the past 5 years, CytomX Therapeutics' Accumulated Depreciation & Amortization registered a high of $16.2 million during Q4 2024, and its lowest value of $11.4 million during Q4 2020.
- For the 5-year period, CytomX Therapeutics' Accumulated Depreciation & Amortization averaged around $14.1 million, with its median value being $14.4 million (2022).
- Per our database at Business Quant, CytomX Therapeutics' Accumulated Depreciation & Amortization surged by 2625.41% in 2020 and then soared by 219.16% in 2023.
- Quarter analysis of 5 years shows CytomX Therapeutics' Accumulated Depreciation & Amortization stood at $11.4 million in 2020, then grew by 21.06% to $13.8 million in 2021, then rose by 3.91% to $14.4 million in 2022, then grew by 2.19% to $14.7 million in 2023, then increased by 10.51% to $16.2 million in 2024.
- Its Accumulated Depreciation & Amortization was $16.2 million in Q4 2024, compared to $14.7 million in Q4 2023 and $14.4 million in Q4 2022.